方盛製藥(603998.SH):獨家創新中藥“玄七健骨片”(註冊分類:中藥1.1類)在2021年獲得了《藥品註冊證書》
格隆匯3月9日丨方盛製藥(603998.SH)於2023年3月7日接受老虎太平洋基金的調研並表示,近年來,公司創新藥與仿製藥雙擎發力,落實創新轉型,持續加大技術創新的投入。創新中藥研發方面,繼“小兒荊杏止咳顆粒”之後,公司自主研發的獨家創新中藥“玄七健骨片”(註冊分類:中藥1.1類)在2021年獲得了《藥品註冊證書》;一致性評價方面,依折麥布片、頭孢克肟片、蒙脱石散、奧美拉唑腸溶片等通過了仿製藥質量和療效一致性評價;目前已提交藥品評審中心進行評審的是諾麗通顆粒。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.